Related Experiment Video
Updated: Apr 7, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
Rashmee Patil1, Mel A Ona2, Haris Papafragkakis2
1Department of Internal Medicine, NYU Lutheran Medical Center, Brooklyn, NY 11220, USA.
Abstract:
The fixed-dose combination of Efavirenz/Emtricitabine/Tenofovir is a first-line agent for the treatment of HIV; however few cases have reported hepatotoxicity associated with the drug. We report a case of Efavirenz/Emtricitabine/Tenofovir-associated hepatotoxicity presenting mainly with hepatocellular injury characterized by extremely elevated aminotransferase levels, which resolved without acute liver failure or need for liver transplant referral.
More Related Videos
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Hepatitis
Drug Toxicity: Risk factors
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drug Toxicity: Overview

